儿童青少年弥漫性毒性甲状腺肿抗甲状腺药物的治疗现状和争议  

Consensus and controversy on antithyroid drug therapy for Graves′disease in children and adolescents

作　　者：李阳[1] 巩纯秀[1] Li Yang;Gong Chunxiu(Department of Endocrinology,Genetics and Metabolism,National Center for Children′s Health(Beijing),Beijing Children′s Hospital,Capital Medical University,Beijing 100045,China)

机构地区：[1]国家儿童医学中心(北京),首都医科大学附属北京儿童医院内分泌遗传代谢科,北京100045

出　　处：《中华实用儿科临床杂志》2024年第10期797-800,共4页Chinese Journal of Applied Clinical Pediatrics

摘　　要：弥漫性毒性甲状腺肿(GD)是儿童甲状腺功能亢进最常见的病因,严重影响儿童正常生长发育,其发生率有逐年增高的趋势。抗甲状腺药物是治疗儿童GD的首选治疗手段,能在短时间内改善免疫紊乱并实现甲状腺功能正常化,但其有诸多问题和争议,面临治疗缓解率低、复发率高和不良反应发生率高的挑战。如何快速实现甲状腺功能正常化,维持治疗疗效实现降低复发率是抗甲状腺药物治疗所面临的重要挑战,需要进一步研究解决有效性和安全性的问题。现就儿童青少年GD抗甲状腺药物的治疗策略、争议和不良反应进行总结与综述。Graves′disease(GD)is the most prevalent cause of hyperthyroidism in children,posing a significant threat to their normal growth and development.The incidence of GD is increasing year by year.Antithyroid drugs are the preferred treatment for GD in children,which can alleviate immune disorders and normalize thyroid function in a short period of time.However,there are still numerous unsolved problems and controversies surrounding this treatment,and the challenges that need to be overcome include the low remission rate,high recurrence rate and high incidence of adverse reactions.The key challenges facing antithyroid drug therapy are how to normalize thyroid function quickly,maintain therapeutic efficacy and reduce recurrence rate,and further studies are needed to improve the effectiveness and safety of the therapy.This article summarizes and reviews the therapeutic strategies,controversies and adverse reactions of antithyroid drugs for GD in children and adolescents.

关 键 词：弥漫性毒性甲状腺肿 Graves′病 治疗 抗甲状腺药物 儿童 青少年 

分 类 号：R725.8[医药卫生—儿科]